Clene (CLNN) Competitors $2.50 -0.10 (-3.85%) Closing price 04:00 PM EasternExtended Trading$2.53 +0.03 (+1.20%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLNN vs. IZTC, XBIT, ENTX, IVVD, CHRS, CRDL, IMUX, ZNTL, KYTX, and ORMPShould you be buying Clene stock or one of its competitors? The main competitors of Clene include Invizyne Technologies (IZTC), XBiotech (XBIT), Entera Bio (ENTX), Invivyd (IVVD), Coherus BioSciences (CHRS), Cardiol Therapeutics (CRDL), Immunic (IMUX), Zentalis Pharmaceuticals (ZNTL), Kyverna Therapeutics (KYTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Clene vs. Invizyne Technologies XBiotech Entera Bio Invivyd Coherus BioSciences Cardiol Therapeutics Immunic Zentalis Pharmaceuticals Kyverna Therapeutics Oramed Pharmaceuticals Clene (NASDAQ:CLNN) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability. Does the media prefer CLNN or IZTC? In the previous week, Clene had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Clene and 0 mentions for Invizyne Technologies. Clene's average media sentiment score of 0.67 beat Invizyne Technologies' score of 0.00 indicating that Clene is being referred to more favorably in the media. Company Overall Sentiment Clene Positive Invizyne Technologies Neutral Does the MarketBeat Community favor CLNN or IZTC? Clene received 84 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformCleneOutperform Votes8481.55% Underperform Votes1918.45%Invizyne TechnologiesN/AN/A Do insiders and institutionals believe in CLNN or IZTC? 23.3% of Clene shares are held by institutional investors. 35.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is CLNN or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. Invizyne Technologies' return on equity of 0.00% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets Clene-8,556.77% -1,106.30% -85.11% Invizyne Technologies N/A N/A N/A Which has higher valuation and earnings, CLNN or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Clene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$350K64.16-$49.50M-$4.04-0.62Invizyne TechnologiesN/AN/AN/AN/AN/A Do analysts rate CLNN or IZTC? Clene presently has a consensus target price of $40.00, suggesting a potential upside of 1,500.00%. Given Clene's stronger consensus rating and higher probable upside, research analysts plainly believe Clene is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryClene beats Invizyne Technologies on 10 of the 13 factors compared between the two stocks. Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLNN vs. The Competition Export to ExcelMetricClenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.46M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.478.9226.8419.71Price / Sales64.16250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book1.206.466.794.50Net Income-$49.50M$143.98M$3.23B$248.18M7 Day Performance-6.02%3.04%4.07%1.14%1 Month Performance-17.22%7.44%12.52%15.20%1 Year Performance-66.22%-2.46%16.83%6.56% Clene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLNNClene2.5375 of 5 stars$2.50-3.8%$40.00+1,500.0%-65.1%$22.46M$350,000.00-0.47100IZTCInvizyne TechnologiesN/A$15.04+11.0%N/AN/A$94.03MN/A0.00N/AGap UpXBITXBiotech0.6102 of 5 stars$3.07+1.0%N/A-65.2%$93.60M$4.01M-2.84100Earnings ReportENTXEntera Bio1.8091 of 5 stars$2.05+1.0%$10.00+387.8%-10.4%$93.18M$223,000.00-7.8820News CoverageIVVDInvivyd2.928 of 5 stars$0.78-0.1%$7.52+869.1%-64.0%$93.04M$25.38M-0.40100Earnings ReportGap DownCHRSCoherus BioSciences3.5853 of 5 stars$0.80+5.1%$4.68+485.4%-60.8%$92.75M$272.25M-10.00330News CoverageAnalyst DowngradeCRDLCardiol Therapeutics1.6121 of 5 stars$1.12+0.9%$8.40+650.0%-48.6%$92.52MN/A-2.8720IMUXImmunic2.4106 of 5 stars$0.960.0%$13.20+1,274.0%-24.5%$92.05MN/A-0.7870Earnings ReportGap DownZNTLZentalis Pharmaceuticals2.085 of 5 stars$1.25-0.8%$8.24+559.6%-89.1%$89.94M$67.43M-0.50160News CoverageEarnings ReportAnalyst RevisionKYTXKyverna Therapeutics2.3587 of 5 stars$2.07-10.8%$18.33+785.7%-83.4%$89.46M$7.03M-0.6196News CoverageAnalyst RevisionGap UpORMPOramed Pharmaceuticals1.7549 of 5 stars$2.14-0.5%N/A-9.3%$87.42M$1.34M19.4510Earnings Report Related Companies and Tools Related Companies IZTC Competitors XBIT Competitors ENTX Competitors IVVD Competitors CHRS Competitors CRDL Competitors IMUX Competitors ZNTL Competitors KYTX Competitors ORMP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLNN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
